A carregar...
Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC
BACKGROUND: The anaplastic lymphoma kinase tyrosine kinase inhibitors (ALK-TKIs) have been administered to patients with ALK-positive non-small cell lung cancer for a long period of time and show a promising response. However, the differences in the toxicity profiles among these drugs are still uncl...
Na minha lista:
| Publicado no: | BMC Cancer |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5469041/ https://ncbi.nlm.nih.gov/pubmed/28606126 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-017-3405-3 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|